Who
Stephen F. Mahoney
President and CEO
Company insider
Files Form 4 as: President and CEO, Viridian Therapeutics; Officer, Dianthus Therapeutics; President & COO, Kiniksa Pharmaceuticals International.
In numbers
- Trades disclosed
- 31
- Buys
- 1
- Sells
- 1
- Bought
- $499K
- Sold
- $39K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 9 Feb 2018
- Last trade
- 3 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Mar 2026filed 9 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $224K7,408 at $30.19 | filing |
| 3 Mar 2026filed 9 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $224K7,408 at $30.19 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code M | —18,357 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $224K7,627 at $29.32 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,357 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,357 at $0.00 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code M | —18,357 | filing |
| 3 Mar 2026filed 4 Mar 2026 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Code F | $224K7,627 at $29.32 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —559,600 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —559,600 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,900 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,900 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —440,565 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,428 at $0.00 | filing |
| 27 Sep 2024filed 30 Sep 2024 | VRDN Viridian TherapeuticsBiotechnology | SEC FORM 4 Bought | $499K21,400 at $23.33 | filing |
| 30 Oct 2023filed 1 Nov 2023 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,259,400 at $0.00 | filing |
| 30 Nov 2022filed 2 Dec 2022 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code A | $2,8203,000 at $0.94 | filing |
| 1 Aug 2022filed 1 Aug 2022 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 17 May 2022filed 19 May 2022 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Viridian Therapeutics (NASDAQ:VRDN) Shares Up 7.8% – Here's WhyVRDN · dailypolitical.com · 19 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Stephen F. Mahoney; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.